France begins recall of ex-Genopharm products as Alkopharm takes over
This article was originally published in Scrip
The French authorities have begun the recall of medicines that were distributed by Genopharm before it was dissolved following the suspension of its operations and those of its sister company Alkopharm on 20 December 2011. Genopharm's assets have been transferred to Alkopharm, which is now responsible for the products concerned.
You may also be interested in...
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by the European pharmaceutical industry federation EFPIA. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.
The EU has published an action plan that is intended to upgrade the bloc’s intellectual property framework while ensuring that goods such as medicines and vaccines are made as widely available as possible. The initiative is part of wide-ranging plans to support member states’ recovery from the pandemic crisis and help ensure the EU’s resilience to future health threats.
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway